{"id":"https://openalex.org/W102662015","doi":null,"title":"Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs.","display_name":"Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs.","publication_year":2007,"publication_date":"2007-06-01","ids":{"openalex":"https://openalex.org/W102662015","mag":"102662015","pmid":"https://pubmed.ncbi.nlm.nih.gov/18705448"},"language":"en","primary_location":{"id":"pmid:18705448","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18705448","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Medical journal of Malaysia","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"W C Tan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W C Tan","raw_affiliation_strings":["Department of Dermatology, Penang Hospital, Penang"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Penang Hospital, Penang","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"C K Ong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C K Ong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"S C Lo Kang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S C Lo Kang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5001545483","display_name":"M Abdul Razak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Abdul Razak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.8993,"has_fulltext":false,"cited_by_count":85,"citation_normalized_percentile":{"value":0.83154698,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"62","issue":"2","first_page":"143","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.7505000233650208,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.7505000233650208,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10038","display_name":"Tuberculosis Research and Epidemiology","score":0.23029999434947968,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-induced-skin-reaction","display_name":"drug-induced skin reaction","score":0.9160000085830688},{"id":"https://openalex.org/keywords/tuberculosis","display_name":"tuberculosis","score":0.6700000166893005},{"id":"https://openalex.org/keywords/pyrazinamide","display_name":"pyrazinamide","score":0.9559999704360962},{"id":"https://openalex.org/keywords/urticaria","display_name":"urticaria","score":0.9390000104904175},{"id":"https://openalex.org/keywords/erythroderma","display_name":"erythroderma","score":0.8289999961853027},{"id":"https://openalex.org/keywords/lichenoid-eruption","display_name":"lichenoid eruption","score":0.9599999785423279},{"id":"https://openalex.org/keywords/hiv-infection","display_name":"HIV infection","score":0.7549999952316284},{"id":"https://openalex.org/keywords/drug-hypersensitivity","display_name":"drug hypersensitivity","score":0.625},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":0.8100000023841858},{"id":"https://openalex.org/keywords/isoniazid","display_name":"isoniazid","score":0.9419999718666077},{"id":"https://openalex.org/keywords/ethambutol","display_name":"ethambutol","score":0.9369999766349792},{"id":"https://openalex.org/keywords/streptomycin","display_name":"streptomycin","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9727120995521545},{"id":"https://openalex.org/C2776228421","wikidata":"https://www.wikidata.org/wiki/Q412318","display_name":"Ethambutol","level":4,"score":0.9184060096740723},{"id":"https://openalex.org/C2780459521","wikidata":"https://www.wikidata.org/wiki/Q417571","display_name":"Pyrazinamide","level":4,"score":0.9016942977905273},{"id":"https://openalex.org/C2776967927","wikidata":"https://www.wikidata.org/wiki/Q423169","display_name":"Isoniazid","level":3,"score":0.6307470798492432},{"id":"https://openalex.org/C2778607973","wikidata":"https://www.wikidata.org/wiki/Q422652","display_name":"Rifampicin","level":3,"score":0.5893856287002563},{"id":"https://openalex.org/C2909018248","wikidata":"https://www.wikidata.org/wiki/Q1363741","display_name":"Exfoliative dermatitis","level":2,"score":0.5597203969955444},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.521690309047699},{"id":"https://openalex.org/C2781069245","wikidata":"https://www.wikidata.org/wiki/Q12204","display_name":"Tuberculosis","level":2,"score":0.43326663970947266},{"id":"https://openalex.org/C2780542314","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Adverse drug reaction","level":3,"score":0.418653279542923},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.41024166345596313},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40908846259117126},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3776184320449829},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2115265429019928},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09482380747795105}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000995","descriptor_name":"Antitubercular Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D004890","descriptor_name":"Erythema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D014581","descriptor_name":"Urticaria","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:18705448","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18705448","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Medical journal of Malaysia","raw_type":"Journal Article"},{"id":"mag:102662015","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18705448","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1988845906","https://openalex.org/W1993523497","https://openalex.org/W2045630842","https://openalex.org/W2067561788","https://openalex.org/W2083048262","https://openalex.org/W2083704008","https://openalex.org/W2087482037","https://openalex.org/W2094036457","https://openalex.org/W2109028417","https://openalex.org/W2135805336","https://openalex.org/W2162696955","https://openalex.org/W2317624504","https://openalex.org/W2321102680","https://openalex.org/W2408076721","https://openalex.org/W4237406238","https://openalex.org/W4321000890"],"related_works":["https://openalex.org/W4313388870","https://openalex.org/W2169327920","https://openalex.org/W4408038209","https://openalex.org/W2093042860","https://openalex.org/W2169942731","https://openalex.org/W4390838328","https://openalex.org/W7171426153","https://openalex.org/W3202922478","https://openalex.org/W4405321938","https://openalex.org/W3214659353"],"abstract_inverted_index":{"First":[0],"line":[1,117],"Anti-TB":[2],"therapy":[3],"with":[4,143],"rifampicin,":[5],"isoniazid,":[6],"pyrazinamide,":[7],"and":[8,24,89,95,135,173],"ethambutol/streptomycin":[9],"is":[10,31,171,192],"very":[11],"effective.":[12],"However,":[13],"major":[14,37],"adverse":[15,27,38],"reactions":[16],"to":[17,58],"antituberculous":[18],"drugs":[19],"can":[20],"cause":[21],"significant":[22],"morbidity":[23],"mortality.":[25],"Cutaneous":[26],"drug":[28,125],"reaction":[29],"(CADR)":[30],"one":[32],"of":[33,47,100,112,141,175,183],"the":[34,45,107,115,122,193],"commonly":[35],"observed":[36,78],"events.":[39],"This":[40],"retrospective":[41],"study":[42],"looked":[43],"at":[44],"cases":[46,176],"TB":[48],"treated":[49,64],"in":[50,187],"Respiratory":[51],"Unit,":[52],"Penang":[53],"Hospital":[54],"from":[55],"January":[56],"2004":[57],"December":[59],"2005.":[60],"Of":[61],"820":[62],"patients":[63,69,142],"for":[65],"active":[66],"TB,":[67],"47":[68],"(25":[70],"females;":[71],"22":[72],"males)":[73],"developed":[74],"CADR":[75,113,144,170],"(5.7%).":[76],"CADRs":[77],"include":[79,92,146],"morbiliform":[80],"rash":[81],"(72.3%),":[82],"erythema":[83],"multiforme":[84],"syndrome":[85],"(8.5%),":[86],"urticaria":[87],"(8.5%)":[88],"others":[90],"(which":[91],"exfoliative":[93],"dermatitis":[94],"lichenoid":[96],"eruption).":[97],"Ninety-seven":[98],"percent":[99],"events":[101],"occurred":[102,177],"within":[103,178],"two":[104,179],"months":[105,180],"after":[106,181],"initial":[108],"dose.":[109],"Incidence":[110],"rate":[111],"among":[114],"first":[116],"anti-TB":[118,184],"drugs,":[119],"pyrazinamide":[120],"was":[121],"commonest":[123,194],"offending":[124,195],"(2.38%),":[126],"followed":[127],"by":[128],"streptomycin":[129],"(1.45%),":[130],"ethambutol":[131],"(1.44%),":[132],"rifampicin":[133],"(1.23%)":[134],"isoniazid":[136],"(0.98%).":[137],"Various":[138],"clinical":[139],"characteristics":[140],"identified":[145],"Human":[147],"Immunodeficiency":[148],"Virus":[149],"(HIV)":[150],"infection":[151],"(27.7%),":[152],"polypharmacy":[153],"(21.3%),":[154],"elderly":[155],"(19.1%),":[156],"autoimmune":[157],"disorders":[158,166],"(6.4%),":[159],"pre-existing":[160,164],"renal":[161],"impairment":[162],"(4.3%),":[163],"liver":[165],"(4.3%).":[167],"In":[168],"conclusion,":[169],"common":[172],"majority":[174],"initiation":[182],"treatment,":[185],"particularly":[186],"HIV":[188],"infected":[189],"patients.":[190],"Pyrazinamide":[191],"drug.":[196]},"counts_by_year":[{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}